Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus

Oncology Nursing Forum

Volumn 38, Issue 2, 2011, Pages 125-127

  Creel, Patricia ^a   Moldawer, Nancy P ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953125363     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/11.onf.125-128     Document Type: Article

References (10)

1. Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., ⋯ Siu, L.L. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95, 1148-1154. (Pubitemid 44660065)
2. Duran, I., Siu, L.L., Oza, A.M., Chung, T.B., Sturgeon, J., Townsley, C.A., ⋯ Niroumand, M. (2006). Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. European Journal of Cancer, 42, 1875-1880. (Pubitemid 44149096)
3. Ellard, S.L., Clemons, M., Gelmon, K.A., Norris, B., Kennecke, H., Chia, S., ⋯ Seymour, L. (2009). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. Journal of Clinical Oncology, 27, 4536-4541.
4. Hudes, G. (2010). Pulmonary toxicity of the rapamycin analog class of mTOR inhibitors. Kidney Cancer Journal, 8, 21-24.
5. Morelon, E., Stern, M., Israël-Biet, D., Correas, J.M., Danel, C., Mamzer-Bruneel, M.F., ⋯ Kreis, H. (2001). Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation, 72, 787-790. (Pubitemid 32879846)
6. National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events [v.4.0]. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE- 4.03-2010-06-14-QuickReference-5x7.pdf
7. Novartis Pharmaceuticals Corporation. (2009). Afinitor® [Prescribing information]. East Hanover, NJ: Author.
8. Pham, P.T., Pham, P.C., Danovitch, G.M., Ross, D.J., Gritsch, H.A., Kendrick, E.A., ⋯ Wilkinson, A.H. (2004). Sirolimus-associated pulmonary toxicity. Transplantation, 77, 1215-1220. (Pubitemid 38580300)
9. Sankhala, K., Mita, A., Kelly, K., Mahalingam, D., Giles, F., & Mita, M. (2009). The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncology, 4, 135-142.
10. Vahid, B., & Marik, P.E. (2008). Pulmonary complications of novel antineoplastic agents. Chest, 133, 528-538. (Pubitemid 351272414)